Tech Company Financing Transactions

Aldagen Funding Round

CNF Investments, Intersouth Partners and Tullis Health Investors invested in a $9 million Series C funding round for Aldagen. The round was announced on 9/13/2007.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series C
Proceeds Purpose
The proceeds raised in this financing will be used to advance the development of Aldagen'sthree clinical-stage products. ALD-101, a unique stem cell therapy derived from cord blood, isbeing tested in an on-going Phase I clinical study to access its safety and ability to improve thespeed and efficacy of cord blood transplantation in the pediatric setting. Aldagen's two otherclinical-stage products, ALD-201 and ALD-301, are potent populations of stem and progenitorcells isolated from a patient's bone marrow. ALD-201 is currently being tested in a Phase I/IIclinical study at the Texas Heart Institute as a therapy for advanced heart failure patients. ALD-301 is being tested in a multi-site ongoing Phase I/II clinical study, which is the first clinical trialinvolving a novel stem cell therapy for critical limb ischemia patients in the United States.

Company Information

Company Status
Acquired or Merged
Mailing Address
2810 Meridian Pkwy. 148
Durham, NC 27713
Email Address
Aldagen is a clinical-stage regenerative medicine company developingand commercializing products to treat vascular and degenerative diseases.The company's proprietary products can identify and isolate potent, highlyeffective adult stem and progenitor cells which can be quickly administeredto regenerate or repair tissue.
Aldagen LinkedIn Company Profile
Social Media
Aldagen Company Twitter Account
Company News
Aldagen News
Aldagen on Facebook
Aldagen on YouTube

Management Team

Email & Social
Chief Executive Officer
Lyle Hohnke
  Lyle Hohnke LinkedIn Profile  Lyle Hohnke Twitter Account  Lyle Hohnke News  Lyle Hohnke on Facebook
Chief Medical Officer
James Hinson
  James Hinson LinkedIn Profile  James Hinson Twitter Account  James Hinson News  James Hinson on Facebook
Chief Operating Officer
Edward Field
  Edward Field LinkedIn Profile  Edward Field Twitter Account  Edward Field News  Edward Field on Facebook



Browse more venture capital transactions:

Prev: 9/13/2007: LDR Holding venture capital transaction
Next: 9/13/2007: Nascentric venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary